Dr. Robin Augustine is an Associate Professor at St. Joseph’s University, Bengaluru, India, and a biomedical researcher specializing in biomaterials, tissue engineering, regenerative medicine, and translational biomedical technologies. He has previously held research positions at Stanford University (USA), University of Massachusetts Lowell (USA), Qatar University (Qatar), and Technion – Israel Institute of Technology (Israel). 

His research focuses on smart biomaterials, electrospun scaffolds, piezoelectric biomaterials, oxygen-generating biomaterials, microneedle-based therapeutics, diabetic wound healing, pancreatic islet transplantation, bone regeneration, and cardiac tissue engineering, with an emphasis on clinical translation. Dr. Augustine has authored over 75 peer-reviewed research articles, several book chapters and books, receiving more than 9,000 citations and achieving an h-index of 53. He has been recognized among the World’s Top 2% Scientists (Stanford University–Elsevier Rankings) and was ranked 76th globally in Biomedical Engineering by Elsevier–Scopus. His honors include the Outstanding Researcher Award from Qatar University, the Council for Higher Education (Israel) Postdoctoral Fellowship, and the SERB National Postdoctoral Fellowship (India). Dr. Augustine earned his Ph.D. in Nanoscience and Nanotechnology from Mahatma Gandhi University, India, and continues to foster international collaborations in biomaterials and regenerative medicine research.

Our Research Focus

Biomaterials Development
We design advanced biomaterials that can interact safely with the human body to promote healing and restore function. Our goal is to address challenges such as chronic wounds, tissue damage, infections, and implant failure through innovative and affordable biomaterial solutions.

Tissue Engineering
We develop engineered scaffolds and bioactive platforms that support the regeneration of damaged tissues and organs. Our research aims to overcome the shortage of donor tissues and improve treatment options for skin, bone, cartilage, and soft tissue defects.

Drug Delivery
We create smart drug delivery systems capable of releasing therapeutic agents in a controlled and targeted manner. Our objective is to improve treatment efficacy while reducing side effects in diseases such as cancer, infections, and chronic inflammatory disorders.

Nanomedicine
We utilize nanotechnology to develop next-generation therapeutics and diagnostic platforms. Our research seeks to enhance precision medicine by enabling targeted treatment, improved bioavailability, and early disease intervention at the cellular and molecular levels.

Bioimaging
We develop advanced imaging agents and platforms for the visualization of biological processes, disease progression, and therapeutic responses. Our goal is to enable early diagnosis, real-time monitoring, and image-guided therapies for improved patient care.